Curis CRIS
NASDAQ CRIS
$1.58 -0.03 (-1.86%)
At close: Aug 21, 2026 · 4:00 PM EDT

Curis (CRIS) Change in Accured Expenses (2010 - 2026)

Curis' (CRIS) quarterly Change in Accured Expenses came in at $521000.0 in Q1 2026, up 79.66% YoY from $290000.0 in Q1 2025, and down 62.71% on a QoQ basis from $1.4 million in Q4 2025.

Curis (CRIS) Change in Accured Expenses (2010 - 2026) Analysis & Trends

Curis (CRIS) has 17 years of Change in Accured Expenses data on file, last reported at $521000.0 in Q1 2026.

  • Quarterly Change in Accured Expenses rose 79.66% year-over-year to $521000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 489.6% YoY) and the FY2025 annual result came in at $2.5 million, up 222.58% from the prior year.
  • Change in Accured Expenses eased to $521000.0 in Q1 2026, from $1.4 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $4.0 million in Q3 2023 to a low of -$3.9 million in Q1 2022.
  • A 5-year average of $26235.3 and a median of $290000.0 in 2025 frame the typical range for Change in Accured Expenses.
  • Annual changes were most pronounced in 2024 — Change in Accured Expenses tumbled 662.39% — and 2025, when it surged 178.31%.
  • Tracing CRIS's Change in Accured Expenses over 5 years: stood at -$3.7 million in 2022, then soared by 93.67% to -$234000.0 in 2023, then plunged by 662.39% to -$1.8 million in 2024, then surged by 178.31% to $1.4 million in 2025, then tumbled by 62.71% to $521000.0 in 2026.
  • The last three Change in Accured Expenses figures came in at $521000.0 (Q1 2026), $1.4 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 222.50 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 492.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 11.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 212.44 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 61.62 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 68.82 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Curis 3.27 Mn -2.35 Mn - -832,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 521,000.00
Mar 31, 2026 521,000.00
Dec 31, 2025 1.40 Mn
Dec 31, 2025 1.40 Mn
Sep 30, 2025 1.03 Mn
Sep 30, 2025 1.03 Mn
Jun 30, 2025 -171,000.00
Jun 30, 2025 -171,000.00
Mar 31, 2025 290,000.00
Mar 31, 2025 290,000.00
Dec 31, 2024 -1.78 Mn
Dec 31, 2024 -1.78 Mn
Sep 30, 2024 2.78 Mn
Sep 30, 2024 2.78 Mn
Jun 30, 2024 -816,000.00
Jun 30, 2024 -816,000.00
Mar 31, 2024 -2.26 Mn
Mar 31, 2024 -2.26 Mn
Dec 31, 2023 -234,000.00
Dec 31, 2023 -234,000.00